JPH0148884B2 - - Google Patents

Info

Publication number: JPH0148884B2
Authority: JP; Japan
Prior art keywords: trifluoromethoxy; benzothiazole; amino; pharmaceutically acceptable; compound
Prior art date: 1980-10-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP56165586A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5795910A (en

Inventor

Mizuru Jatsuku

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmindustrie

Original Assignee

Pharmindustrie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-10-17

Filing date

1981-10-16

Publication date

1989-10-20

1981-10-16 Application filed by Pharmindustrie filed Critical Pharmindustrie

1982-06-15 Publication of JPS5795910A publication Critical patent/JPS5795910A/ja

1989-10-20 Publication of JPH0148884B2 publication Critical patent/JPH0148884B2/ja

Status Granted legal-status Critical Current

Links

FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 10
239000001961 anticonvulsive agent Substances 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 4
229940125681 anticonvulsant agent Drugs 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
239000002249 anxiolytic agent Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims 2
150000001875 compounds Chemical class 0.000 description 13
239000000203 mixture Substances 0.000 description 11
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
206010010904 Convulsion Diseases 0.000 description 7
230000036461 convulsion Effects 0.000 description 7
239000008187 granular material Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
239000003814 drug Substances 0.000 description 6
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 5
241001279009 Strychnos toxifera Species 0.000 description 5
230000000694 effects Effects 0.000 description 5
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
229960005453 strychnine Drugs 0.000 description 5
239000013543 active substance Substances 0.000 description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 3
230000001773 anti-convulsant effect Effects 0.000 description 3
229960003965 antiepileptics Drugs 0.000 description 3
229940049706 benzodiazepine Drugs 0.000 description 3
229960003692 gamma aminobutyric acid Drugs 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000005303 weighing Methods 0.000 description 3
XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
-1 benzodiazepines Chemical class 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229960003350 isoniazid Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
229940116357 potassium thiocyanate Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108050007496 Shikimate kinase 2 Proteins 0.000 description 1
241000906446 Theraps Species 0.000 description 1
YGCODSQDUUUKIV-UHFFFAOYSA-N Zoxazolamine Chemical compound ClC1=CC=C2OC(N)=NC2=C1 YGCODSQDUUUKIV-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
230000005611 electricity Effects 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
229960000604 valproic acid Drugs 0.000 description 1
229950006967 zoxazolamine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicinal Preparation (AREA)

JP56165586A 1980-10-17 1981-10-16 Novel medicine containing benzothiazole compound Granted JPS5795910A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8022218A FR2492258A1 (fr)	1980-10-17	1980-10-17	Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole

Publications (2)

Publication Number	Publication Date
JPS5795910A JPS5795910A (en)	1982-06-15
JPH0148884B2 true JPH0148884B2 (2)	1989-10-20

Family

ID=9247013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP56165586A Granted JPS5795910A (en)	1980-10-17	1981-10-16	Novel medicine containing benzothiazole compound

Country Status (16)

Country	Link
US (1)	US4370338A (2)
EP (1)	EP0050551B1 (2)
JP (1)	JPS5795910A (2)
AR (1)	AR227069A1 (2)
AU (1)	AU545437B2 (2)
CA (1)	CA1166159A (2)
DE (1)	DE3163230D1 (2)
DK (1)	DK444281A (2)
FR (1)	FR2492258A1 (2)
GR (1)	GR75804B (2)
HU (1)	HU184893B (2)
IL (1)	IL63880A0 (2)
MA (1)	MA19364A1 (2)
NO (1)	NO813492L (2)
PT (1)	PT73828B (2)
ZA (1)	ZA817187B (2)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826860A (en) *	1987-03-16	1989-05-02	Warner-Lambert Company	Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
FR2619712B1 (fr) *	1987-08-25	1990-08-31	Rhone Poulenc Sante	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
FR2619713B1 (fr) *	1987-08-25	1990-08-31	Rhone Poulenc Sante	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
FR2640624B1 (fr) *	1988-12-15	1994-08-12	Rhone Poulenc Sante	Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
US5236940A (en) *	1988-12-15	1993-08-17	Rhone-Poulenc Sante	Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
FR2640623B1 (fr) *	1988-12-15	1991-03-22	Rhone Poulenc Sante	Derives de la benzothiazoline, leurs procedes de preparation et les medicaments les contenant
DE68901859T2 (de) *	1988-12-15	1993-01-14	Rhone Poulenc Sante	2-benzothiazolamin-derivate enthaltende arzneimittel, verbindungen und ihre herstellung.
FR2640622B1 (fr) *	1988-12-15	1991-03-22	Rhone Poulenc Sante	Derives de l'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2649705B2 (fr) *	1989-07-13	1994-09-23	Rhone Poulenc Sante	Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
ES2052954T3 (es) *	1988-12-15	1994-07-16	Rhone Poulenc Sante	Derivados de imino-2-polifluoroalcoxi-6-benzotiazol, sus procedimientos de preparacion y los medicamentos que les contienen.
FR2649703B1 (fr) *	1989-07-13	1991-11-22	Rhone Poulenc Sante	Derives d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procedes de preparation et les medicaments les contenant
FR2649701B2 (fr) *	1988-12-15	1991-11-22	Rhone Poulenc Sante	Derives d'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2661910B1 (fr) *	1990-05-11	1992-08-21	Rhone Poulenc Sante	Derives d'imino-2 heterocyclylalkyl-3 benzothiazoline, leur preparation et les medicaments les contenant.
FR2649702B1 (fr) *	1989-07-13	1991-11-22	Rhone Poulenc Sante	Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
EP0409692B1 (fr) *	1989-07-13	1994-03-09	Rhone-Poulenc Sante	Dérivés d'imino-2 hétérocyclylalkyl-3 benzothiazoline, leur préparation et les médicaments les contenant
FR2649704B1 (fr) *	1989-07-13	1991-11-22	Rhone Poulenc Sante	Derives d'imino-2 ethyl-3 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
US5260297A (en) *	1989-07-13	1993-11-09	Rhone Poulenc Rorer, S.A.	2-imino-3-alkylbenzothiazoline derivatives bearing a heterocyclic substituent on the alkyl group, their preparation and medicinal products containing them.
FR2662160B1 (fr) *	1990-05-18	1992-07-24	Rhone Poulenc Sante	Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
FR2662694A1 (fr) *	1990-06-05	1991-12-06	Rhone Poulenc Sante	Derives du benzoselenazole, leur preparation et les medicaments les contenant.
FR2663030A1 (fr) *	1990-06-05	1991-12-13	Rhone Poulenc Sante	Derives selenies de benzothiazoline leur preparation et les medicaments les contenant.
FR2662695A1 (fr) *	1990-06-05	1991-12-06	Rhone Poulenc Sante	Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant.
FR2663029B1 (fr) *	1990-06-07	1992-07-31	Rhone Poulenc Sante	Derives de benzothiazole, leur preparation et les medicaments les contenant.
FR2688138B1 (fr) *	1992-03-06	1995-05-05	Rhone Poulenc Rorer Sa	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
FR2699077B1 (fr) *	1992-12-16	1995-01-13	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700117B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2700116B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants comme radioprotecteurs.
FR2702148B1 (fr) *	1993-03-05	1995-04-07	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2726271B1 (fr) *	1994-10-26	1996-12-06	Rhone Poulenc Rorer Sa	Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
FR2786101B1 (fr)	1998-11-24	2002-07-05	Aventis Laboratoire	Utilisation de la nicergoline dans le traitement de la spasticite
FR2787028B1 (fr)	1998-12-15	2002-10-18	Aventis Pharma Sa	Utilisation du riluzole dans le traitement des traumatismes acoustiques
WO2000041728A1 (en) *	1999-01-12	2000-07-20	Takeda Chemical Industries, Ltd.	Compositions for treating frequent urination and urinary incontinence
JP2004514699A (ja) *	2000-11-30	2004-05-20	ファイザー・プロダクツ・インク	Ｇａｂａアゴニストおよびソルビトールデヒドロゲナーゼ阻害剤の組合せ
SK6092003A3 (en)	2000-11-30	2004-07-07	Pfizer Prod Inc	Combination of GABA agonists and aldosereductase inhibitors
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
JP2006528676A (ja) *	2003-05-16	2006-12-21	ファイザー・プロダクツ・インク	非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ
PL1691811T3 (pl)	2003-12-11	2014-12-31	Sunovion Pharmaceuticals Inc	Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
CA2553291A1 (en) *	2004-01-29	2005-09-09	Pfizer Products Inc.	Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
EP2201963B1 (en) *	2005-04-05	2016-01-27	Yale University	Glutamate modulating agents in the treatment of mental disorders
US9629817B2 (en)	2005-08-25	2017-04-25	Steven Michael Weiss	Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en)	2005-10-21	2012-06-20	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) *	2005-10-31	2008-07-16	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
CA2643199A1 (en) *	2006-03-08	2007-09-13	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) *	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
MX2008014320A (es) *	2006-05-09	2009-03-25	Braincells Inc	Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
BRPI0716604A2 (pt) *	2006-09-08	2013-04-09	Braincells Inc	combinaÇÕes contendo um derivado de 4-acilaminopiridina
AU2007299920A1 (en) *	2006-09-19	2008-03-27	Braincells, Inc.	PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20080108827A1 (en) *	2006-10-25	2008-05-08	Padi Pratap R	Process for preparing riluzole
RS55585B1 (sr)	2006-11-22	2017-06-30	Clinical Research Associates LLC	Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
US20090167322A1 (en) *	2007-12-28	2009-07-02	Erik Edmund Magnuson	Systems and method for classifying a substance
ES2388827T3 (es) *	2008-04-03	2012-10-19	F. Hoffmann-La Roche Ag	Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2284161A1 (en)	2009-07-21	2011-02-16	Edmond Pharma S.R.L.	Process for the preparation of riluzole
BR112017010423B1 (pt)	2014-11-21	2023-09-26	Biohaven Pharmaceutical Holding Company Ltd.	Formulação sublingual de riluzol e uso da mesma
JP2017535612A (ja) *	2014-11-21	2017-11-30	バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎＰｈａｒｍａｃｅｕｔｉｃａｌＨｏｌｄｉｎｇＣｏｍｐａｎｙＬｔｄ．	リルゾールの舌下投与
JP6830671B6 (ja)	2015-09-23	2021-03-10	エックスダブリューファルマリミテッド	γ−ヒドロキシ酪酸（ＧＨＢ）のプロドラッグ、その組成物および使用
TWI788307B (zh)	2016-10-31	2023-01-01	美商艾歐凡斯生物治療公司	用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
ES3055314T3 (en)	2017-01-06	2026-02-11	Iovance Biotherapeutics Inc	Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
CN115025086A (zh)	2017-03-30	2022-09-09	凯瑞康宁生物工程（武汉）有限公司	双环杂芳基衍生物及其制备与用途
CN112004802B (zh)	2018-09-30	2021-12-28	凯瑞康宁生物工程（武汉）有限公司	作为神经元组胺受体-3拮抗剂的化合物及其用途
KR102881504B1 (ko)	2019-12-20	2025-11-06	엑스더블유파마 리미티드	4-발레릴옥시부티르산의 합성 방법
US11304906B2 (en)	2020-06-18	2022-04-19	XWPharma Ltd.	Controlled release granulations of water-soluble active pharmaceutical ingredients
EP4167966A1 (en)	2020-06-18	2023-04-26	XWPharma Ltd.	Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
US11896573B2 (en)	2020-07-24	2024-02-13	XWPharma Ltd.	Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
KR20230058151A (ko)	2020-10-05	2023-05-02	엑스더블유파마 리미티드	감마-하이드록시부티르산 유도체의 변형된 방출 조성물
AU2022238423B9 (en)	2021-03-19	2025-12-18	XWPharma Ltd.	Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3879531A (en) *	1972-07-17	1975-04-22	Uniroyal Inc	2-aminothiazoles compositions and methods for using them as psychotherapeutic agents
US3876653A (en) *	1973-03-26	1975-04-08	Kyowa Hakko Kogyo Kk	Benzothiazole derivatives

1980
- 1980-10-17 FR FR8022218A patent/FR2492258A1/fr active Granted
1981
- 1981-09-18 IL IL63880A patent/IL63880A0/xx not_active IP Right Cessation
- 1981-10-01 GR GR66186A patent/GR75804B/el unknown
- 1981-10-05 US US06/308,695 patent/US4370338A/en not_active Expired - Lifetime
- 1981-10-07 DK DK444281A patent/DK444281A/da not_active Application Discontinuation
- 1981-10-09 DE DE8181401564T patent/DE3163230D1/de not_active Expired
- 1981-10-09 EP EP81401564A patent/EP0050551B1/fr not_active Expired
- 1981-10-15 PT PT73828A patent/PT73828B/pt unknown
- 1981-10-15 CA CA000387977A patent/CA1166159A/fr not_active Expired
- 1981-10-16 ZA ZA817187A patent/ZA817187B/xx unknown
- 1981-10-16 NO NO813492A patent/NO813492L/no unknown
- 1981-10-16 JP JP56165586A patent/JPS5795910A/ja active Granted
- 1981-10-16 HU HU812994A patent/HU184893B/hu not_active IP Right Cessation
- 1981-10-16 AU AU76545/81A patent/AU545437B2/en not_active Ceased
- 1981-10-16 MA MA19508A patent/MA19364A1/fr unknown
- 1981-10-19 AR AR287142A patent/AR227069A1/es active

Also Published As

Publication number	Publication date
GR75804B (2)	1984-08-02
MA19364A1 (fr)	1982-07-01
AU545437B2 (en)	1985-07-11
ZA817187B (en)	1982-09-29
AU7654581A (en)	1982-04-22
EP0050551B1 (fr)	1984-04-18
CA1166159A (fr)	1984-04-24
PT73828A (fr)	1981-11-01
FR2492258B1 (2)	1982-11-26
US4370338A (en)	1983-01-25
EP0050551A1 (fr)	1982-04-28
DE3163230D1 (en)	1984-05-24
PT73828B (fr)	1983-01-17
DK444281A (da)	1982-04-18
JPS5795910A (en)	1982-06-15
IL63880A0 (en)	1981-12-31
AR227069A1 (es)	1982-09-15
HU184893B (en)	1984-10-29
FR2492258A1 (fr)	1982-04-23
NO813492L (no)	1982-04-19

Publication	Publication Date	Title
JPH0148884B2 (2)	1989-10-20
EP2459176B1 (en)	2017-09-27	Crystallization method and bioavailability
EP0011489B1 (en)	1982-12-15	An analgesic effervescent powder and process for its preparation
BG64938B1 (bg)	2006-10-31	Състави на база celecoxib
AU2016324482A1 (en)	2018-03-29	Crystallization method and bioavailability
US6197341B1 (en)	2001-03-06	Formulations of balsalazide and its derivatives
LV13114B (en)	2004-06-20	Wet granulation formulation for bisphosphonic acids
HU200096B (en)	1990-04-28	Process for producing pharmaceutical compositions containing micronized ebselen cristals
PL212072B1 (pl)	2012-08-31	Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
SK281193B6 (sk)	2001-01-18	Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy
JP2002501015A (ja)	2002-01-15	リーシュマニア症の治療における経口投与のためのミルテフォシンを含有する固形医薬品
JPS63130569A (ja)	1988-06-02	カルボン酸アミド含有薬剤
KR0147855B1 (ko)	1998-08-17	골형성 촉진제
WO2017208070A1 (en)	2017-12-07	Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
US3297527A (en)	1967-01-10	Propargylamine as an anti-depressant
EP0123520B1 (en)	1988-08-17	Process for preparing base salts of piroxicam deposited on a pharmaceutically-acceptable carrier
HU193845B (en)	1987-12-28	Process for preparing synergic pharmaceutical preparations comprising flupyrthine and 4-acetamido-phenol
US4153691A (en)	1979-05-08	Analgesic and anti-inflammatory compositions
US3266988A (en)	1966-08-16	Method of producing anti-adrenal activity
JP3090211B2 (ja)	2000-09-18	第４級ｎ−ベンジル−ｎ−｛２−〔２−（（１ｓ，５ｓ）−６，６−ジメチルビシクロ〔３．１．１〕−ヘプト−２−イル）エトキシ〕エチル｝モルホリニウム塩を含有する胃保護作用を有する製薬学的調剤およびその製造法
JPS6051449B2 (ja)	1985-11-14	サリチル酸コリンを含有する安定な固体薬剤及びその製造法
US3452141A (en)	1969-06-24	Methods of treating pain with n**alpha-phthaloyl-alpha-amino acid amides
JPH02311422A (ja)	1990-12-27	コリン・アセチル転移酵素活性賦活剤
RU2224521C2 (ru)	2004-02-27	Твердая лекарственная форма, обладающая транквилизирующим действием, и способ ее изготовления
US3264183A (en)	1966-08-02	Process for effecting diuresis